Precision Optics (POCI) Q4 2026 earnings review
Precision Optics fixes its margins just as growth stops
Precision Optics Corporation, the maker of optical instruments for medical and aerospace customers, fixed its manufacturing snags but lost its top-line momentum. Revenue climbed 42% for the quarter, and gross margins expanded sharply as the company finally solved production bottlenecks on its single-use medical scopes. That discipline pushed the business to its second straight quarter of positive adjusted profit.
| Revenue | $8.8M +42% from a year ago |
|---|---|
| Gross margin | 25% +12 points from a year ago |
| Adjusted profit (EBITDA) | $0.4M loss of $0.9M a year ago |
| Full-year revenue outlook | Flat middle of the range: $31.5M |
⚖️ Verdict: 🔴 Bearish
The story got worse because the company's largest customer hit the brakes. While the operational turnaround is working beautifully in the background, a top-tier satellite customer paused orders for the first half of the new fiscal year. That single pullback erased the company's expected growth, pushing the full-year outlook to flat.
The question now is whether the medical device pipeline can scale fast enough to reduce this extreme customer concentration. If it does, the company can grow even when a major client pauses; if it does not, Precision Optics remains captive to one satellite maker's inventory cycles. The second-half order book will tell.
🐂 Bull Case
The Production Engine Is Fixed
The company resolved the manufacturing snags that crippled its gross margins earlier in the year. Gross margin reached 25% this quarter, up from 13% a year ago and a significant recovery from the low single digits seen two quarters ago.
That operational discipline drove Precision Optics to its second straight quarter of positive adjusted operating profit, delivering $400,000 this quarter. The business is finally large enough to cover its fixed costs when the production lines run smoothly.
What to watch: whether gross margins hold near 25% while the top customer pauses orders over the next six months.
Medical Programs Are Scaling
Production revenue outside the paused satellite program is still growing. Total production sales hit $8.0 million this quarter, up 57% from a year ago.
The company continues to ramp its single-use cystoscopy systems and is beginning production on a newer single-use ophthalmic program. Management also secured a fresh engineering order from a second space technology customer, which points to a recovering product development pipeline.
What to watch: the gap between production revenue and engineering revenue. If the medical programs scale cleanly, production revenue will offset the satellite weakness by the second half of the year.
🐻 Bear Case
One Customer Paused, and Growth Stopped
Management warned last quarter that its top aerospace customer needed to slow down deliveries. The full impact is now visible: the company's own plan expects no top-line growth at all next year.
The company frames the pause as a temporary bottleneck on the customer's end. Yet the numbers show that when the top satellite program halts, the entire company's growth goes with it. The full-year outlook calls for revenue right in line with the $31.5 million just delivered, erasing a streak of 40%-plus growth.
What to watch: second-half revenue, which management says will show the customer's return.
Customer Concentration Risk Bit Hard
The flat outlook proves the risk of relying on two giant programs to carry the business. Medical endoscopes and satellite optics generated nearly all of the company's recent growth.
Because these customers are too large to name publicly, readers have no way to verify if the aerospace client is simply clearing excess inventory or if they found a cheaper supplier. The lack of transparency makes the revenue floor hard to predict.
What to watch: the quarterly filing's customer concentration table, which will show exactly how much of total sales were tied to this single aerospace buyer.
👓 Other Themes
Capital structure changed
The company's cash balance climbed to $9.8 million from $1.8 million a year ago. The increase comes entirely from an oversubscribed public offering completed in March, which fortified the balance sheet but heavily diluted existing owners.
💲 Other KPIs
Up 42% from a year ago. The company issued millions of new shares during its spring public offering to secure the cash needed to fund its manufacturing expansion.
Up 37% from a year ago. The balance sheet expanded alongside the record production volumes, though receivables grew slightly slower than the 42% increase in quarterly revenue.
🔮 Guidance
New. The middle of the range points to zero growth compared to the $31.5 million just delivered. The plan assumes a weak first half caused by the aerospace customer's pause, followed by a stronger second half when orders are expected to resume.
New. The outlook calls for an operating loss excluding one-offs. While better than the $2.1 million lost this year, it implies the company will likely slip back below break-even during the first half while the satellite orders are paused.
❓ Key Questions
When exactly does the aerospace customer return?
Management expects orders to resume in the second half, but it is unclear if this is backed by a firm contract commitment or just a hopeful forecast.
Where is the Unity platform?
The proprietary development platform was supposed to shorten the time to production, but it went unmentioned in the release after showing slow adoption earlier this year.
How much did tariffs boost revenue?
The company previously passed tariff costs through to customers. The release does not clarify how much of the record top line came from these pass-throughs rather than higher unit volumes.